175 related articles for article (PubMed ID: 35269680)
1. Effects of Ruxolitinib and Calcitriol Combination Treatment on Various Molecular Subtypes of Breast Cancer.
Schneider J; Jeon YW; Suh YJ; Lim ST
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269680
[TBL] [Abstract][Full Text] [Related]
2. Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor‑positive, human epidermal growth factor receptor 2‑positive breast cancer cells.
Lim ST; Jeon YW; Gwak H; Kim SY; Suh YJ
Mol Med Rep; 2018 Apr; 17(4):5581-5588. PubMed ID: 29436642
[TBL] [Abstract][Full Text] [Related]
3. Combined treatment with ruxolitinib and MK-2206 inhibits the JAK2/STAT5 and PI3K/AKT pathways via apoptosis in MDA-MB-231 breast cancer cell line.
Guvenir Celik E; Eroglu O
Mol Biol Rep; 2023 Jan; 50(1):319-329. PubMed ID: 36331743
[TBL] [Abstract][Full Text] [Related]
4. Quercetin-loaded solid lipid nanoparticles exhibit antitumor activity and suppress the proliferation of triple-negative MDA-MB 231 breast cancer cells: implications for invasive breast cancer treatment.
Hatami M; Kouchak M; Kheirollah A; Khorsandi L; Rashidi M
Mol Biol Rep; 2023 Nov; 50(11):9417-9430. PubMed ID: 37831347
[TBL] [Abstract][Full Text] [Related]
5. Berberine and Evodiamine Act Synergistically Against Human Breast Cancer MCF-7 Cells by Inducing Cell Cycle Arrest and Apoptosis.
Du J; Sun Y; Lu YY; Lau E; Zhao M; Zhou QM; Su SB
Anticancer Res; 2017 Nov; 37(11):6141-6151. PubMed ID: 29061795
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of anticancer activities of Poria cocos ethanol extract in breast cancer: In vivo and in vitro, identification and mechanism.
Jiang Y; Fan L
J Ethnopharmacol; 2020 Jul; 257():112851. PubMed ID: 32283190
[TBL] [Abstract][Full Text] [Related]
7. Platinum complexes inhibit HER-2 enriched and triple-negative breast cancer cells metabolism to suppress growth, stemness and migration by targeting PKM/LDHA and CCND1/BCL2/ATG3 signaling pathways.
Bai X; Ali A; Lv Z; Wang N; Zhao X; Hao H; Zhang Y; Rahman FU
Eur J Med Chem; 2021 Nov; 224():113689. PubMed ID: 34293698
[TBL] [Abstract][Full Text] [Related]
8. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
9. A Comparative Study of the Anticancer Activity and PARP-1 Inhibiting Effect of Benzofuran-Pyrazole Scaffold and Its Nano-Sized Particles in Human Breast Cancer Cells.
Anwar MM; Abd El-Karim SS; Mahmoud AH; Amr AEE; Al-Omar MA
Molecules; 2019 Jun; 24(13):. PubMed ID: 31261939
[TBL] [Abstract][Full Text] [Related]
10. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
[TBL] [Abstract][Full Text] [Related]
11. Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells.
Segovia-Mendoza M; Díaz L; González-González ME; Martínez-Reza I; García-Quiroz J; Prado-Garcia H; Ibarra-Sánchez MJ; Esparza-López J; Larrea F; García-Becerra R
J Steroid Biochem Mol Biol; 2015 Apr; 148():122-31. PubMed ID: 25510900
[TBL] [Abstract][Full Text] [Related]
12. Different mechanisms involved in the berberine-induced antiproliferation effects in triple-negative breast cancer cell lines.
Lin YS; Chiu YC; Tsai YH; Tsai YF; Wang JY; Tseng LM; Chiu JH
J Cell Biochem; 2019 Aug; 120(8):13531-13544. PubMed ID: 30957305
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
14. Metformin induces unique biological and molecular responses in triple negative breast cancer cells.
Liu B; Fan Z; Edgerton SM; Deng XS; Alimova IN; Lind SE; Thor AD
Cell Cycle; 2009 Jul; 8(13):2031-40. PubMed ID: 19440038
[TBL] [Abstract][Full Text] [Related]
15. Antineoplastic effects of α-santalol on estrogen receptor-positive and estrogen receptor-negative breast cancer cells through cell cycle arrest at G2/M phase and induction of apoptosis.
Santha S; Bommareddy A; Rule B; Guillermo R; Kaushik RS; Young A; Dwivedi C
PLoS One; 2013; 8(2):e56982. PubMed ID: 23451128
[TBL] [Abstract][Full Text] [Related]
16. Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway.
Li T; Xiong Y; Wang Q; Chen F; Zeng Y; Yu X; Wang Y; Zhou F; Zhou Y
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4001-4011. PubMed ID: 31588803
[TBL] [Abstract][Full Text] [Related]
17. Induction of AMPK activation by N,N'-diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers.
Johnson J; Rychahou P; Sviripa VM; Weiss HL; Liu C; Watt DS; Evers BM
PLoS One; 2019; 14(3):e0209392. PubMed ID: 30875375
[TBL] [Abstract][Full Text] [Related]
18. Adeno-associated virus type 2 infection of nude mouse human breast cancer xenograft induces necrotic death and inhibits tumor growth.
Alam S; Bowser BS; Israr M; Conway MJ; Meyers C
Cancer Biol Ther; 2014 Aug; 15(8):1013-28. PubMed ID: 24834917
[TBL] [Abstract][Full Text] [Related]
19. 8-Chloro-Adenosine Inhibits Proliferation of MDA-MB-231 and SK-BR-3 Breast Cancer Cells by Regulating ADAR1/p53 Signaling Pathway.
Ding HY; Yang WY; Zhang LH; Li L; Xie F; Li HY; Chen XY; Tu Z; Li Y; Chen Y; Yang SY
Cell Transplant; 2020; 29():963689720958656. PubMed ID: 32907379
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy of calcitriol inhibits the proliferation of breast cancer cells: new concept of nonclassical function of calcitriol.
Aljunidee KA; Bardaweel SK
Horm Mol Biol Clin Investig; 2021 Nov; 43(2):199-205. PubMed ID: 34768317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
